Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

作者：Ian Frank, Shuying S. Li, Nicole Grunenberg, Edgar T. Overton, Samuel T. Robinson, Hua Zheng, Kelly E. Seaton, Jack Heptinstall, Mary Allen, Kenneth H. Mayer, Daniel A. Culver, Michael C. Keefer, Sri Edupuganti, Michael Pensiero, Vijay Mehra, Stephen C. De Rosa, Daryl E. Morris, Shixia Wang, Michael S. Seaman, David C. Montefiori, Guido Ferrari, Georgia D. Tomaras, James G. Kublin, Lawrence Corey, Shan Lu · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(24)00036-5 · 被引用次数：10 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions